N-Cyclopropylmethyl-3,4-methylenedioxyamphetamine | 22698-08-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: N-Cyclopropylmethyl-3,4-methylenedioxyamphetamine
• 英文别名: Methylenedioxycyclopropylmethylamphetamine；1-(1,3-benzodioxol-5-yl)-N-(cyclopropylmethyl)propan-2-amine
• CAS: 22698-08-4
• 化学式: C₁₄H₁₉NO₂
• 分子量: 233.31
• InChiKey: AEIQNPMGFQNZNV-UHFFFAOYSA-N

物化性质

• 沸点：
  342.8±11.0 °C(Predicted)
• 密度：
  1.138±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  胡椒基丙酮 、 环丙基甲胺.盐酸盐 在 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 反应 36.0h， 生成 N-Cyclopropylmethyl-3,4-methylenedioxyamphetamine
  参考文献：
  名称：

  3,4-亚甲基二氧基苯基异丙胺（3,4-亚甲基二氧基苯丙胺）的中枢活性N-取代类似物。

  摘要：

  3，4-亚甲基二氧基苯基异丙基胺及其N-甲基同系物的已知中枢神经系统活性促使合成一系列在氮原子上具有取代基的类似物。这些类似物的大多数（R =烷基，烯基，羟基，烷氧基和烷氧基烷基）是通过3,4-亚甲基二氧基苯基丙酮与适当的胺和氰基硼氢化钠进行还原性烷基化反应制备的。受阻异构体是间接合成的。在几种动物试验和人类受试者中对它们的药理活性的测量表明，中央活性随N取代基体积的增加而降低。

  DOI：

  10.1002/jps.2600690220

文献信息

• Braun; Shulgin; Braun, Arzneimittel-Forschung/Drug Research, 1980, vol. 30, # 5, p. 825 - 830
  作者：Braun、Shulgin、Braun

  DOI：——

  日期：——
• Antiparkinsonian Action of Phenylisopropylamines
  申请人：Caron G. Marc

  公开号：US20070027208A1

  公开（公告）日：2007-02-01

  A method of treating a subject for Parkinson's disease comprises administering said subject a phenylisopropylamine in an amount effective to treat said Parkinson's disease. In some embodiments the method is used to treat at least a motor symptom of Parkinson's disease; in some embodiments the method is used to treat at least a non-motor symptom of Parkinson's disease.
• TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH
  申请人：STAMETS Paul Edward

  公开号：US20210145851A1

  公开（公告）日：2021-05-20

  Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum ) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica , or Cannabis ruderalis , optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.
• US8877802B2
  申请人：——

  公开号：US8877802B2

  公开（公告）日：2014-11-04
• [EN] TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH<br/>[FR] COMPOSITIONS DE TRYPTAMINES DESTINÉES À AMÉLIORER L'EXCROISSANCE DES NEURITES
  申请人：STAMETS PAUL EDWARD

  公开号：WO2021101926A1

  公开（公告）日：2021-05-27

  Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.